News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Inspire Pharmaceuticals (ISPH) Announces Development And License Agreement With Boehringer Ingelheim Pharma GmbH & Co. KG For Intranasal Epinastine In The United States And Canada


2/21/2006 10:47:06 AM

DURHAM, N.C.--(BUSINESS WIRE)--Feb. 21, 2006--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has entered into a development and license agreement with Boehringer Ingelheim International GmbH. Inspire will acquire certain exclusive rights to develop and market an intranasal dosage form of epinastine in the United States and Canada for the treatment or prevention of rhinitis.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES